A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response

Journal of Virology

Volumn 76, Issue 2, 2002, Pages 644-655

  Peng Fei Zhang, ^a   Bouma, P ^a   Eun Ju Park, ^a   Margolick, J B ^a   Robinson, J E ^a   Zolla Pazner, S ^a   Flora, M N ^a   Quinnan G V , Jr ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SYNTHETIC PEPTIDE; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING SITE; CONFORMATION; CROSS REACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD4; CELL LINE; CROSS REACTIONS; CYCLIZATION; DNA, RECOMBINANT; EPITOPES; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMANS; IMMUNE SERA; MUTATION; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; PHENOTYPE;

EID: 0036140259     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.2.644-655.2002     Document Type: Article

References (54)

1. Prevalence of human immunodeficiency virus type 1 p24 antigen in U.S. blood donors - An assessment of the efficacy of testing in donor screening
2. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120
3. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries
4. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization
5. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
6. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas
7. Local and global structural properties of the HIV-MN V3 loop
8. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D
9. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates
10. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
11. Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: An international collaboration
12. Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains
13. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein
14. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4
15. Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies
16. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex
17. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site
18. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody
19. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades
20. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity
21. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
22. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies
23. CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2
24. The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants
25. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies
26. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity
27. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
28. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain
29. Progress in the development of an HIV-1 vaccine
30. + by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins
31. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein
32. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies
33. Influence of proline residues on protein conformation
34. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay
35. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B
36. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: A new strategy for studying the immunologic relatedness of HIV-1
37. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains
38. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes
39. Distinct mechanisms mediating enhanced infectivity and envelope conformational change determine global neutralization resistance phenotype of human immunodeficiency virus type 1
40. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1
41. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120
42. Immunization against viral diseases
43. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response
44. Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants
45. A role for carbohydrates in immune evasion in AIDS
46. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization
47. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120
48. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
49. Preparation and characterization of human HIV type 1 neutralizing reference sera
50. Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1
51. Use of Fmoc-N-(2-hydroxy-4-methoxybenzyl)amino acids in peptide synthesis
52. Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection
53. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy
54. The principal neutralizing determinant of HIV-1 located in V3 of gp120 forms a 12-residue loop by internal hydrophobic interactions